Powerful perspectives
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles
Data & publication
Autotaxin inhibition with IOA-289 decreases breast tumor growth in mice whereas knockout of autotaxin in adipocytes does not
Data & publication
TLR-X (IOA-359) attenuates steatosis and fibrosis in a preclinical NASH model
Data & publication
IOA-289, an orally available type IV autotaxin inhibitor, ameliorates steatosis and fibrosis in a progressive preclinical murine NASH model
Data & publication
Patient derived tumor cells identify mechanistically rational combinations for the PI3Kδ inhibitor roginolisib in solid and hematologic malignancies
Data & publication
Highly selective allosteric modulator of the phosphoinositide 3-kinase data (PI3Kδ) roginolisib (IOA-244) in a dose escalation study of patients with refractory/relapsed follicular lymphoma (FL)
Data & publication
First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B)
Data & publication
Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors
Press release
iOnctura to present research at leading scientific conferences in June 2023
Press release
Peer-reviewed translational research paves the way for first-in-class autotaxin inhibitor IOA-289 in cancer
Press release
iOnctura expands pipeline and receives development grant from Health Holland and KWF
Data & publication
IOA-244 is a non–ATP-competitive, highly selective, tolerable PI3K delta inhibitor that targets solid tumors and breaks immune tolerance
Press release
iOnctura awarded UK’s MHRA innovation passport for entry into innovative licensing and access pathway (ILAP)
Looking for media
resources?